Navidea Awarded an Additional NIH SBIR Grant for NAV4694 Beta-Amyloid Imaging Agent for Study in Mild Cognitive Impairment Sep 4, 2013
Navidea Biopharmaceuticals Announces Agreement with FDA on Special Protocol Assessments for NAV5001 Phase 3 Program Aug 22, 2013
Navidea Awarded NIH SBIR Grant for NAV4694 Beta-Amyloid Imaging Agent Phase 3 Clinical Program Aimed at Alzheimer’s Disease Aug 21, 2013
Navidea Biopharmaceuticals Signs Manufacturing Agreement with Siemens’ PETNET Solutions for NAV4694 Beta-amyloid Imaging Agent Aug 21, 2013
Navidea Biopharmaceuticals Announces Centers for Medicare & Medicaid Services (CMS) Issuance of Lymphoseek® Reimbursement Pass-Through C Code, Effective as of October 1, 2013 Aug 20, 2013
Navidea Biopharmaceuticals to Announce Second Quarter 2013 Financial Results Pre-market on Wednesday, August 7, 2013 Jul 25, 2013
Navidea Biopharmaceuticals Highlights New Data for NAV4694 PET β-Amyloid Imaging Agent Presented at AAIC 2013 Jul 22, 2013
Navidea Biopharmaceuticals’ NAV4694 β-Amyloid Imaging Agent to Be Used in Alzheimer’s Disease Studies by Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) Jul 16, 2013
